Invitae Stock – A Pure-Play on Genetics Testing

We research and write about tech companies and stocks religiously, but we’ve learned the hard way that trying to cherry-pick winning stocks is a high-risk game. No matter how promising the thesis, every company can potentially implode. In an attempt to weed out the land mines, we look for companies with strong industry partnerships (as opposed to a bunch of MOUs that never go anywhere), consistent revenue growth that demonstrates traction, and large total addressable markets. That’s exactly what we saw in ArcherDX, a precision oncology company that planned to have an IPO (initial public offering) before being acquired just days ago. Naturally, we wanted to take a closer look at the life sciences company they merged with – Invitae (NVTA).

About Invitae

Founded in 2010, San Francisco based Invitae is a leading medical genetics company that took in nearly $200 million in funding before going public in 20